Xu Zhenyu, Chief Scientific Officer of SOPHiA GENETICS SA (NASDAQ:SOPH), filed a Form 4 on August 21, 2026, reporting the sale of 20,000 ordinary shares across three transactions between August 19 and August 21, 2026.

Key Highlights

  • Three sales over three days: Xu Zhenyu disposed of 10,000 shares on August 19, 4,592 shares on August 20, and 5,408 shares on August 21, 2026.
  • Weighted average prices: Shares sold at a weighted average of $7.9427 on August 19, $8.4078 on August 20, and $8.4036 on August 21.
  • Rule 10b5-1 plan: All three transactions were made pursuant to a duly adopted trading plan under Rule 10b5-1(c).
  • Remaining ownership: Following the transactions, Xu Zhenyu directly holds 566,887 ordinary shares.
  • Price ranges: Individual transaction prices ranged from $7.90 to $8.01 on August 19, $8.40 to $8.43 on August 20, and $8.40 to $8.42 on August 21.

Xu Zhenyu's Three-Day Share Sale at SOPHiA GENETICS

According to the filing, Xu Zhenyu, serving as Chief Scientific Officer of SOPHiA GENETICS SA, sold a combined 20,000 ordinary shares in direct transactions over three consecutive trading days. The filing identifies all three sales with transaction code "S" and notes they were conducted under a pre-established Rule 10b5-1(c) trading plan.

The filing discloses that each reported price is a weighted average, as the shares were sold in multiple transactions within a stated price range on each day. For the August 19 sale of 10,000 shares, individual prices ranged from $7.90 to $8.01, producing a weighted average of $7.9427. On August 20, 4,592 shares were sold at prices from $8.40 to $8.43, with a weighted average of $8.4078. On August 21, the remaining 5,408 shares were sold at prices from $8.40 to $8.42, with a weighted average of $8.4036. The reporting person has undertaken to provide full per-price breakdowns to the issuer, any security holder, or SEC staff upon written request, according to the filing.

After all reported transactions, Xu Zhenyu directly beneficially owns 566,887 ordinary shares, as stated in the filing. The form was signed by Elimara Brunetto as attorney-in-fact for Zhenyu Xu on August 21, 2026. No derivative securities transactions were reported in Table II of the filing.

What Was Disclosed

The filing reports three open-market sales of SOPHiA GENETICS ordinary shares by the company's Chief Scientific Officer between August 19 and August 21, 2026, totaling 20,000 shares, all executed under a Rule 10b5-1(c) trading plan, with 566,887 shares remaining held directly afterward.